文献速递心律失常

阵发性房颤标准与增强消融减少复发的随机试验

Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence: The AWARE Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2023-01-01

AWARE 试验在加拿大 10 个大学附属中心纳入 398 例症状性阵发性房颤患者,随机接受标准单环或增强双环肺静脉隔离消融。

要点

  • 双环 WACA 较单环 WACA 未改善阵发性房颤消融后无复发生存。
  • 1 年复发率两组接近,差异无统计学意义。
  • 重复消融率与严重不良事件在两组间相近。

核心结论

  • 在阵发性房颤患者中,采用双环消融 lesion set 的额外消融未较标准单环消融改善免于复发性房性心律失常。

研究设计与样本

  • 实用性、多中心、前瞻性、随机、开放标签、盲法终点、优效性临床试验,在加拿大 10 个大学附属中心开展。
  • 2015 年 3 月至 2017 年 5 月纳入 18 岁及以上症状性阵发性房颤患者,按 1:1 随机分组,分析按意向性治疗进行。
  • 单环 WACA 组 195 例(平均年龄 60.6 [9.3] 岁,女性 65 例 [33.3%]),双环 WACA 组 203 例(平均年龄 61.5 [9.3] 岁,女性 66 例 [32.5%])。

主要发现

  • 单环 WACA 组 20 例(10.3%)与双环 WACA 组 15 例(7.4%)接受重复导管消融(相对危险度 0.72;95%CI 0.38-1.36)。
  • 经判定的严重不良事件在单环 WACA 组 13 例(6.7%)与双环 WACA 组 14 例(6.9%)发生。

关键数值与推荐

  • 主要终点为消融后 91 至 365 天之间的房性心律失常复发。
  • 患者消融后接受 42 天动态心电图监测。

临床怎么用

  • 对症状性阵发性房颤行肺静脉隔离时,采用双环 WACA 额外消融未显示优于标准单环 WACA 的临床获益。
  • 重复消融与严重不良事件在两组间相近,不支持仅以扩大消融范围作为常规策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Recurrent atrial fibrillation (AF) commonly occurs after catheter ablation and is associated with patient morbidity and health care costs. OBJECTIVE: To evaluate the superiority of an augmented double wide-area circumferential ablation (WACA) compared with a standard single WACA in preventing recurrent atrial arrhythmias (AA) (atrial tachycardia, atrial flutter, or atrial fibrillation [AF]) in patients with paroxysmal AF. DESIGN, SETTING, AND PARTICIPANTS: This was a pragmatic, multicenter, prospective, randomized, open, blinded end point superiority clinical trial conducted at 10 university-affiliated centers in Canada. The trial enrolled patients 18 years and older with symptomatic paroxysmal AF from March 2015 to May 2017. Analysis took place between January and April 2022. Analyses were intention to treat. INTERVENTIONS: Patients were randomized (1:1) to receive radiofrequency catheter ablation for pulmonary vein isolation with either a standard single WACA or an augmented double WACA. MAIN OUTCOMES AND MEASURES: The primary outcome was AA recurrence between 91 and 365 days postablation. Patients underwent 42 days of ambulatory electrocardiography monitoring after ablation. Secondary outcomes included need for repeated catheter ablation and procedural and safety variables. RESULTS: Of 398 patients, 195 were randomized to the single WACA (control) arm (mean [SD] age, 60.6 [9.3] years; 65 [33.3%] female) and 203 to the double WACA (experimental) arm (mean [SD] age, 61.5 [9.3] years; 66 [32.5%] female). Overall, 52 patients (26.7%) in the single WACA arm and 50 patients (24.6%) in the double WACA arm had recurrent AA at 1 year (relative risk, 0.92; 95% CI, 0.66-1.29; P = .64). Twenty patients (10.3%) in the single WACA arm and 15 patients (7.4%) in the double WACA arm underwent repeated catheter ablation (relative risk, 0.72; 95% CI, 0.38-1.36). Adjudicated serious adverse events occurred in 13 patients (6.7%) in the single WACA arm and 14 patients (6.9%) in the double WACA arm. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with paroxysmal AF, additional ablation by performing a double ablation lesion set did not result in improved freedom from recurrent AA compared with a standard single ablation set. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02150902.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Nair GM, Birnie DH, Nery PB, et al. Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence: The AWARE Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 36947030. doi:10.1001/jamacardio.2023.0212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。